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FOREWORD  
Abdominal aortic aneurysm is a major cause of morbidity and mortality among men 
in the Western countries, particularly in men older than 65 years. In most cases the 
aneurysm is asymptomatic, and remains undetected until rupture. The mortality rate 
of a ruptured aneurysm is high. The overall mortality from AAA can be reduced by 
early detection through screening programmes and elective repair. Ultrasound is 
considered practical for screening. The method is available, but the cost-effectiveness 
in Norway is unknown.  
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ABSTRACT 
Background: Abdominal aortic aneurysm is the 10th leading cause of death 
representing 1.3% of all fatalities among men aged 65-85 in the Western countries. 
Screening procedures are available, but the cost-effectiveness for Norway is 
unknown. 
Objective: To predict the costs and impact on life expectancy of an AAA screening 
program. 
Methods: A Markov model was developed to compare the effect of a single 
ultrasound screening for a cohort of men at the age 65 with the current no screening 
strategy. The following health states were included: AAA≤30 mm, AAA30–39 mm, 
AAA40–54 mm, AAA55-59 mm,  AAA≥60 mm with risk factors, AAA>60 mm with 
unknown risk factors, Inoperable AAA55-59 mm, Inoperable AAA≥60 mm , Post 
EVAR (patients who survive endovascular repair will transit to this health state after 
repair), Dead from aneurysm and Dead from other causes. Transition probabilities 
were derived from the medical literature and the cycle length was one year. 
Incremental cost per life year gained was calculated and sensitivity analysis and 
discounting of future effects were performed. 
Outcome measures: The results are expressed as incremental costs, incremental life 
years gained and cost per life year gained. 
Results: The average life time AAA-related cost of a 65-year-old patient in the non-
screening group was NOK3010 (NOK2032 discounted) and in the screening group 
NOK6074 (NOK4686 discounted), resulting in incremental costs of NOK2654 per 
screened patient. The life expectancy was 16.3832 (11.7051 discounted) for non-
screened patients and 16.4351 (11.7345 discounted) for screened, or a life year 
gained of 0.0294. The cost per life year gained was NOK90300. 
The results of the one-way sensitivity analyses indicate that the conclusion is not 
threatened by any realistic change of the model input. 
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Interpretation/conclusion: One-time ultrasonography screening for AAA men at the 
age 65 appears to be cost-effective. 
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1. INTRODUCTION 
Abdominal aortic aneurysm (AAA) is a common condition that affects approximately 
2-9% of men and 1-2% of women. AAA is the 10th leading cause of death (1.3%) 
among men aged 65-85 in the Western countries. The aneurysms are typically 
asymptomatic, but the aneurysm may evolve and eventually rupture. A rupture of 
aneurysm is associated with high mortality and most patients die before they come to 
surgery. These deaths can be prevented by early detection through screening 
programmes and elective repair.  
This thesis will start by describing abdominal aortic aneurysm and its pathogenesis in 
chapter 1. In chapter 2, it will describe the epidemiology of the disorder, while 
Chapter 3 and 4 explore various diagnostic and therapeutic strategies. Chapter 5 
explains the basic concepts of economic evaluation, and in chapter 6 the research 
question is explicitly defined. The methods are described in chapter 7, including some 
basic theory of Markov modelling, a description of the structure of the model and an 
overview of the literature search. Finally, the results and discussion are presented in 
chapters 8 and 9. 
1.1 Aortic aneurysm 
“An aneurysm is defined as a focal dilation of the aorta involving an increase in 
diameter of at least 50 percent as compared to the expected normal diameter” (Ernst 
1993). An aortic aneurysm is a general term for any abnormal expansion of the aorta, 
caused by a weakening in an artery wall as blood is pumped through it. The 
weakening of the artery wall is most frequently a result of atherosclerosis, while other 
causes will also be explained later in this thesis.   
 10
1.2 Anatomy and physiology of aorta 
Aorta is the main artery of the body and plays a key role in the cardiovascular system. 
It arises from the left ventricle of the heart and carries blood out to all organs in the 
body. In addition to aorta, there are also various other types of vessels in the 
cardiovascular system: arteries (aorta and branches of the aorta), arterioles, 
capillaries, venules and veins. All blood vessels have the same basic structure with 
three layers of wall: one interior layer (tunica intima), one middle layer (tunica 
media), and one outer layer (tunica externa). Tunica intima consists of a layer of 
endothelial cells and a thin layer of connective tissue. Tunica media consists of 
varying amount of vascular smooth muscle, while tunica externa is entirely made of 
connective tissue. A normal aortic diameter is approximately 17-21 mm (infrarenal) 
for men and 15-19 mm (infrarenal) for women and the wall of the aorta is 1,5 mm 
thick, but the dimension will depend on various factors such as sex, age and blood 
pressure (Bjålie, Haug, & Sjaastad 2000;Moore 2006). 
Aorta is divided into three different parts: aorta ascendens, arcus aortae and aorta 
descendens. Aorta ascendens is the part which departs from the left ventricle and is 
ascending to the arcus aortae. Arcus aortae cross to aorta descendens, which pass 
downward along the vertebral column and through the diaphragm. Aorta thoracalis is 
the area of aorta above diaphragm, while aorta below diaphragm is named abdominal 
aorta (aorta abdominalis) (Bjålie, Haug, & Sjaastad 2000). 
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Figure 1: Structure of the Aorta 
 
 
1.3 Atherosclerosis 
Atherosclerosis is the most frequent type of arteriosclerosis, which means dense 
arteries (Næss 2002). Atherosclerosis is characterized with congestion of lipids, 
particularly cholesterol in the intima of the artery.  The lipids are absorbed by 
macrophages21, but will also stay outside the macrophages and create crystals of 
cholesterol. The macrophages secrete growth factors, which induce the plain muscle 
cells in the area to divide. The alteration can be seen as yellow plaques. The process 
                                              
21 A type of white blood cells that ingests foreign material. 
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may be reversible, but generally it evolves. Progressively, the plaques will elevate, as 
a form of a cushion, above the surface of intima. The lipids, within and outside the 
macrophages, will irritate the artery wall and cause inflammation. Gradually, it will 
develop a bulge which will narrow the lumen of the artery and create stenosis. 
Occasionally, the plaque below intima will rupture and develop into an ulcer (plaque 
rupture). As the atherosclerosis process progresses, the alteration will also occur in 
the media and the entire artery wall will be weakened (Næss 2002). The 
atherosclerosis process may eventually cause thrombosis in the arteries. A thrombosis 
does often cause a block in the blood stream and infarction. Thrombosis in the legs 
blocks the blood from flowing back to the heart and causes a congestion of blood 
which cause swelling of the legs and severe pain. If the thrombosis occurs in the heart 
or in the brain it may lead to infarction of the heart or cerebral infarction. Thrombosis 
may also occur in the aorta, but because of the size dimension of the aorta, it will not 
cause a complete block in the blood stream but is identified as a focal dilation of the 
artery, called aneurysm. Aneurysms are round (saccular) or more often tube like 
(fusiform) and the latter is most frequent. 
The stretched vessels may be symptom free, but may also cause discomfort as 
abdominal and back pain. Additionally, compression of nerve roots can cause leg 
pain of numbness. Untreated aneurysms will become progressively larger. As the 
aneurysms evolve, the risk for rupture increases. A rupture causes severe pain, 
massive internal hemorrhage, and death within minutes or hours unless the patient 
has successful surgery. The risk of rupture depends on the size. The risk is large once 
the aneurysm has reached approximately 5 cm, but some may also swell to over 15 
cm before they rupture (Krohg-Sørensen 2001). 
 
1.3.1 Risk factors 
From epidemiological screening studies, risk factors for atherosclerosis and AAA 
have been identified. Smoking is probably one of the most important environmental 
risk factors (Sakalihasan, Limet, & Defawe 2005). Case control studies report that 
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there is significant clinical association between smoking and the presence of AAA. 
Genetic factors do also seem to have important effects. Kuivaniemi and co-workers 
report that the disorder is present 15-19% in the first-degree relatives, but the 
frequency is only 1-3% in unrelated patients (Kuivaniemi et al. 2003). 
 Other risk factors are hypertension, hyperlipdaemia, coronary artery disease, history 
of lower extremity bypass operation, claudication, ischemic rest pain and carotid 
artery disease, trauma, elevated cholesterol level and overweight (Berkow, Fletcher, 
& Beers 1997;Lee et al. 2002). 
Aortic aneurism has traditionally been regarded as a consequence of atherosclerosis. 
However, this conventional view has been challenged in recent years. Firstly, 
aneurysms have been associated with inflammation in the vessel wall or injuries in 
intima or media. Marfans syndrome is a disease which attacks the connective tissue. 
The disease is a congenital weakness in the vessel walls which cause the aneurysm. 
The weakening of the layer of the aortic wall can also be a consequence of 
inflammatory diseases such as syphilis and tuberculosis. However, such cases are rare 
in Norway because of the low prevalence of those diseases.     
The aneurysms increase exponentially and the risk of rupture increases with size. 
1.3.2 Classification of aneurysms 
Aortic aneurysm is classified according to the anatomic location. Aortic root 
aneurysm appears on the aortic root (the sinuses of Valsalva), while the thoracic aorta 
aneurysms are found on the thoracic aorta. The most common form of aortic 
aneurysm is abdominal aortic aneurysm (AAA). Three quarters of all aneurysms 
develop in this segment, which runs from the diagphram to the lower abdomen, 
where aorta divides into two iliac arteries. One may also experience aortic aneurysms 
which involve both the thoracic and abdominal aorta (thoracabdominal aortic 
aneurysm). One reason that AAA is more common than thoracic aorta, is that content 
elastin is lower in the abdominal aorta. Elastin is an important load-bearing protein in 
connective tissue and is found in the wall of aorta (Næss 2002). Its elastic property 
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allows many tissues in the body to resume their shape after stretching or contracting. 
Another explanation of higher frequency of AAA than other types of aneurysm is that 
the abdominal aorta does not possess blood vessels, and repair is therefore hindered 
(van der Vliet & Boll 1997). 
Figure 2: Illustration of aorta with large abdominal aneurysm 
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2. EPIDEMIOLOGY 
Abdominal aorta aneurysm occurs mostly among men older than 65 years, and has 
been claimed to cause 1.3% of all deaths among men in the age of 65-85 in developed 
countries(Lundholm J. et al. 1999;Sakalihasan, Limet, & Defawe 2005). Statistics 
Norway report that 301 men aged 65 and older died from AAA (or similar diseases in 
the same category) in 2005 (Statistics Norway 2005c). At the same time, the number 
of deaths among women were only 177(Statistics Norway 2005a). Although AAA is 
estimated to be the tenth most common cause of mortality, the estimates of mortality 
may be hampered by low rates of post mortems. Sudden ruptures are likely to be 
certified as cardiac death in the absence of autopsy, when AAA was not documented 
ante mortem and may affect the reported number of deaths (Bergqvist, Bjorck, & 
Wanhainen 2008).  
2.1 Incidence of Abdominal aortic aneurysm 
The incidence of AAA is by some argued to have increased during the past two 
decades. Zankl and co-workers point out the importance of a widespread surveillance 
of AAA. In recent years, an increasing number of mostly asymptomatic patients have 
been detected during routine abdominal screening and may contribute to an increase 
in the incidence (Zankl et al. 2007). Sakalihasasn and co-workers argue that due to 
the ageing of the population, the rise in the number of smokers, and improved 
diagnostic tools, the reported incidence of abdominal aorta aneurism has increased 
(Sakalihasan, Limet, & Defawe 2005). This is in contrast with trends seen in stroke 
and coronary heart disease (Norman et al. 2004). Hence, it is difficult to predict any 
specific numbers on the incidence. However, one does know that the incidence 
increases with age and as the disorder is categorized as a “lifestyle disease”, the 
incidence will to some extent be reflected by the lifestyle of the population 
(Sakalihasan, Limet, & Defawe 2005). 
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One difficulty with investigating the incidence is that one needs to make a repetitive 
measurement of the probabilities. This is both time and cost consuming. In order to 
measure the number of new cases of AAA, one also needs to screen the target group 
before they develop the disease. In real life it is difficult to predict who these persons 
will be. 
2.2 Prevalence of Abdominal aortic aneurysm 
Few epidemiological studies of AAA have been done in Norway in recent years. 
However, a population-based study in Tromsø in Norway found that an aneurysm 
was present in 2.2 % of the women and 8.9 % of the men (Singh et al. 2001). The 
study reports age and sex specific prevalence rates. For men aged 55-64, 65-74 and 
75-84 the percentage of subjects with AAA were 6.2, 14.1 and 19.8 respectively. For 
the same age groups the percentage of women with AAA was 0.7, 4.2 and 5.2 
respectively. The prevalence of AAA is higher among men than women. From the 
Tromsø study the prevalence is estimated to be four times higher among men than 
women (Singh, Bonaa, Jacobsen, Bjork, & Solberg 2001). This is also supported by 
similar international studies (Lederle, Johnson, & Wilson 2001). 
The prevalence numbers from Norway are somewhat higher compared to other 
countries. International prevalence rates are estimated between 1.0-2.2 for women 
and 1.3-8.9% for men (Zankl, Schumacher, Krumsdorf, Katus, Jahn, & Tiefenbacher 
2007). As we have few epidemiological studies on AAA in Norway, we do not know 
if the variation is due to the design of the study or a matter of epidemiological and 
demographic differences between the countries. 
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3. DIAGNOSIS 
About half of the deaths that are attributed to rupture take place before the patient 
reaches the hospital (Ashton et al. 2002;Silverstein et al. 2005). Among those who 
reach the hospital alive, less than half survive the emergency repair (Ashton, Buxton, 
Day, Kim, Marteau, Scott, Thompson, & Walker 2002;Lundholm J., Hatlinghus S., 
Wirsching J, Amundsen S., Staxrud L.E., Gjølberg T., Hafsahl G., Oskarsson W., 
Krohg-Sørensen, Brekke M., & Myhre H.O. 1999). Elective repair is reported to be 
more successful than emergency repair, and hence the purpose of treatment is to 
detect the aneurysm before it ruptures (Ashton, Buxton, Day, Kim, Marteau, Scott, 
Thompson, & Walker 2002). The aneurysms is mainly detected during routine 
physical examination (palpation of abdomen) or found incidentally through routine 
medical tests, when evaluating other diseases such as lung diseases.  
Abdominal palpation is the original method to detect AAA (Lederle & Simel 1999). 
Palpation is the use of doctor’s hands to detect alteration in the size of the organs. 
Palpation has low costs, as no further equipment is required. However, the accuracy 
is often limited by patient obesity and the sensitivity and specificity will vary with the 
experience of the doctor (Lynch 2008). Furthermore, the sensitivity rate increases 
with the size of the aneurysm and presence of any recognisable risk factors and 
characteristics of the patient. One single report indicates that the physical 
examination has a sensitivity rate which ranged from 33% to 100%, while the 
specificity ranged from 75% to 100% (Lynch 2008). Palpation, as diagnostic tool, 
results therefore in a large proportion of false-negative and false-positive findings and 
a consequent poor positive predictive value (PPV).22 In the same report the PPV 
ranged from 14% to 100% 
Maximal aneurysm diameter is the often considered as the best predictor of rupture 
and the decision on repair is mainly based on this measurement (Sprouse et al. 2003). 
                                              
22 PPV measures the proportion of patients with positive test results who are correctly  
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A size difference of only few millimeters determines whether or not a patient is 
offered surgery. Hence, the sensitivity and specificity is of great importance. The 
principal modalities used to measure AAAs are ultrasonography (US) and computed 
tomography (CT) (Sprouse, Meier, III, Lesar, DeMasi, Sood, Parent, Marcinzyck, & 
Gayle 2003). Both methods reproduce measurements which are within an adequate 
range. 
3.1 Ultrasonography  
Abdominal ultrasonography is an ultrasound-based diagnostic imaging technique 
used to examine the interior of the abdomen. The technique involves exposing part of 
the body to high-frequency sound waves to produce pictures of the inside of the body. 
Unlike x-ray, the individual is not exposed to ionizing and the method is painless and 
supposedly safe.  
The sensitivity and specificity of ultrasonography are both close to 100% when 
compared with operative findings (Silverstein, Pitts, Chaikof, & Ballard 2005). Still, 
in some cases, the aorta can not be visualized due to bowel gas, obesity or periaortic 
disease (Ernst 1993;Silverstein, Pitts, Chaikof, & Ballard 2005).  The technique is 
often imprecise in measuring the size of the aneurysm. The size is important for 
prognostic reasons, but is also essential in determining the growth rate of the 
aneurysm.  
Interobserver variability in measurements obtained by ultrasonography is reported to 
range from 0.22 to 1.55 cm (Knaut et al. 2005).  Singh and co-workers indicate that 
both the intra- and inter-observer variability were less than 4 mm in measurements of 
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aximal infrarenal23 aortic diameter. However, the inter-and intra-observer 
variability24 will vary with experience among sonographers (Singh et al. 1998). 
Ultrasonography provides structural detail of vessel walls and atherosclerotic plaque. 
Its adva t of 
significant side effects.  
Figure 3: Ultrasonography images of an infrarenal aortic aneurysm 
ntage is that it is easily available and transportable, and is absen
 
3.2 Computed tomography  
Unlike ultrasonography, computed tomography (CT) uses x-rays (ionising radiation) 
to create cross sectional images of the abdominal area. The individual will be asked 
to lie down so that the small detectors inside the CT scanner, can measure the amount 
of x-rays that make it through the abdomen. The information from detectors 
                                              
23 Infrarenal means located below the kidneys. 
24 Interobserver variability is defined as the degree of divergence between two or more observers, while intraobserver 
variability is defines as the degree of divergence within one observer.  
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undergoes sophisticated computer analyses that allow the creation of several 
individual images, which are called slices.  
Computed tomography is also recognized with sensitivity and specificity close to 
100% compared to operative findings (Silverstein, Pitts, Chaikof, & Ballard 2005). 
Several authors have noted a difference between AAA measurements obtained with 
ultrasonography and CT. CT is more accurate in estimating the aneurysm size than 
ultrasonography and considered as the gold standard, although evidence is lacking 
(Silverstein, Pitts, Chaikof, & Ballard 2005;Singh et al. 2004). The reproducibility 
rate of CT is also reported to be somewhat higher than for ultrasonography. Knaut 
and co-workers report that the inter-observer variability obtained by CT range from 
0.28 to ers report 
that the absolute intra-observer difference of the maximal infrarenal aortic diameter 
was 2 mm or less in 94% of intra-observer pairs (Singh et al. 2003). 
 
Figure 4: Computed tomography images of abdominal aortic aneurysm 
0.70 cm  (Knaut, Kendall, Patten, & Ray 2005). Singh and co-work
 
 
Variability is caused by differences in observer expertise, time of testing, method of 
measurement and the definition of the measurement size (Singh, Jacobsen, Solberg, 
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Kumar, & Arnesen 2004). Moreover, a precise correlation between CT and 
ultrasonography is difficult because of the real time variation in the aortic diameter, 
due to differences in the pulsatile flow phases through the vessel.  
Generally, ultrasound tends to slightly underestimate the aortic diameter, although 
this phenomenon is taken into consideration in the literature. Ultrasound is considered 
 
h devices do not have the same level of specificity and 
sensitivity, when it comes to predict which of the detected aneurysm that will rupture 
and cause death. These issues may be important when considering whether or not to 
A. Further considerations are also discussed in 
the following chapter. 
ic 
Regardless of which part that initiated the contact, the doctors need to assume the 
 process to be 
g criteria:  
 
2. A generally acceptable method of treatment must be available 
practical for screening, whereas CT is the preferred method for preoperative imaging
in patients with AAAs (Vidakovic et al. 2007). I will go further into the methods used 
in my model in chapter 7. 
Although, it is reported that both ultrasound and CT have specificity and sensitivity 
close to 100%, it should be noted that the specificity and sensitivity only concerns the 
size of the aneurysm. Bot
implement a screening program for AA
3.3 Screening and ethics 
The World Health organization (WHO) has defined screening as “a medical 
investigation which does not arise from a patient’s request for advice for specif
symptoms or complaints”(Wilson & Jungner 1968). 
In contrast to traditional medical practice, in which the patient asks the doctor for 
advice and treatment, the contact is now initiated by the health care providers. 
same duty of care and that the patients must hold the same understanding of what the 
treatment involves. Hence, certain criteria are required for a screening
undertaken. WHO has suggested the followin
1. The disease should be an important health problem
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3. The policy of treatment must be clear 
4. Provision for diagnosis and treatment must be available 
5. The disease must have a detectable latent stage 
6. A suitable screening method must be available 
. The natural course of the disease must be known. 
 needs 
 is 
ent 
rs, reducing 
health expenditures has been on the top agenda, and screening may be seen as one 
test and 
n 
f the 
7. The screening method must be accepted by the target population 
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9. The program must be cost-effective 
10. The treatment of the disease should favour the prognosis of the patients  
 
These criteria will be comprehensively evaluated later in this thesis, when discussing 
the results from the analysis. However, the essence of the criteria is that disease
to be sufficiently important, and that the outcome of the treatment at the 
presymptomatic stage benefits the patient. In other words; the purpose of screening
to identify the disease or risk factor in its preclinical stage, in order to improve 
morbidity and mortality and to gain a long term benefit in terms of avoided treatm
in the future. The benefit can also involve reduced costs. In recent yea
strategy in fighting this challenge. Treatment at an early stage may not only have 
positive effects on the patient’s health, but may also be cost-saving.  
Unfortunately, screening does not always live up to the expectations in the previous 
paragraph, as screening also involves “psychological costs”. There are particular 
three aspects which cause these “psychological costs”; patients do not understand 
precisely what the test is for, they are not acquainted with the accuracy of the 
they are not familiar with what the test results imply (Marteau 1990). Patients, who 
receive an invitation to a screening programme, may experience induced anxiety i
the sense that an invitation make people feel ill when they really are healthy. 
Furthermore, the patients should know what the sensitivity and specificity rates o
test are, and warned that a test can never produce perfect results (Edward & Hall 
1992). Induced anxiety can also be experienced both for false positive and false 
negative results. Because there is a trade off between false reassurance and false 
alarms, this does not mean that each patient will benefit from screening (Mant & 
 23
Fowler 1990). In the case of a positive result one need to make sure that the pa
explained the consequences of such a result. For most patients a positive result will 
involve either surveillance or elective repair. However, some patients will also be 
considered as unfit for repair, because their aneurysm is less than the defined 
threshold for repair, and some are also inoperable due to risk factors. These patients 
need to continue on living knowing that they have a “time bomb” in their stomach. 
The “psychological costs” of the screening program for these patients are not to be 
neglected. The “time bomb” may go off at any time and without notice, and the only 
way to control them perfectly is serial measurements. Patients who have a d
aneurysm will, however, have ultrasound examination only four times to once a
For a patient who thought he was perfectly well and then is left with the knowledge 
that he has a life threatening disease, the surveillance program may not be 
experienced as comprehensive and adequate (Brearly S. & Johnson J.N 2008). 
Furthermore, patients must be familiar with that an attendance in a screening program
also involves several follow-ups. If the patient does not have this informati
tient is 
etected 
 year. 
 
on, it may 
lead to induced anxiety when they receive additional invitations. In general one need 
ctical 
a 
s 
larger part of people’s life can be defined as relevant for medical 
intervention and become part of the area of responsibility of the health care sector. 
to weight the effect of the patients who get their aneurysm detected and benefit from 
elective against the effect of those who are considered as unfit for repair.  
Another ethical issue of screening is the phenomena often referred to as 
medicalization. Medicalization means, literary, “to make medical”, but in pra
manner the concept also has a wider meaning. In recent years, concepts of health and 
disease have extended their meaning to involve a broader aspect of people’s life and 
the medical field of responsibility. This field of responsibility involves both 
knowledge and tasks, and includes the right to define what should be considered as 
disease (Lian Olaug S. 2006). Medicalization can also be looked upon as the proces
which causes an extensive use of medical expertise and terminology. As a result of 
the phenomena a 
This may not only be problematic for ethical reasons, but may also cause excessive 
health expenses. 
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In order to achieve an effective
sufficiently trained, that there e
 screening program it is important that the staff is 
xists protocols for positive results and a united 
agreement on how the patients should be managed.  
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4. TREATMENT 
depend on the size and location of the 
aneurysm, as well as the person's general health, including age and risk. Treatment 
ptions include surveillance and surgery. 
urveillance is considered as the appropriate option for patients with small 
aneurysms. The classification of aneurysms varies, but in Norway one monitors 
pproximately 55 mm (Lundholm J., Hatlinghus 
., Wirsching J, Amundsen S., Staxrud L.E., Gjølberg T., Hafsahl G., Oskarsson W., 
Krohg-Sørensen, Brekke M., & Myhre H.O. 1999;Statistics Norway 2005c). This 
 as “watching-and-waiting”, as the patient 
 monitored through ultrasound or CT once or more a year. Surgery is the 
recommended treatment strategy for patients with aneurysms larger than 55 mm and 
Boris Sobolev PhD 2003). There are mainly two approaches to treat abdominal aortic 
d 
d 
 
. 
Treatment for an aortic aneurysm will 
o
S
patients until they reach the size of a
S
kind of treatments is sometimes referred to
is
for those with rapidly increasing aneurysm (Brown P.T.MD, David T.Zelt MD, & 
aneurysm; open abdominal surgery and endovascular surgery. 
4.1 Open abdominal surgery 
Open abdominal surgery is the conventional surgery strategy for AAA (Bosch et al. 
2002;Scott et al. 1995).The procedure involves that the vascular surgeon makes a 
large cut in the abdominal wall to identify the aorta at the site of the aneurysm an
clamps the aorta to keep it from bleeding. The surgeon now replaces the weakene
area with a graft, which is sewn in place with permanent suture material. The graft is 
artificial (dacron or goretex) and will replace the aorta and secure the arterial
circulation to the pelvic and the lower extremities (Medline Plus Encyclopedia 2008)
The length and risk of the surgery will depend on the extent of the aneurysm and the 
patient’s health. Most patients stay in the hospital for one week and the recovery time 
is usually one month to six weeks.  
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Figure 5: Illustration of open repair stent graft 
 
 
 
                  
 
 
 
 Endovascular surgery 
 
 the 
il 
n a video 
pen 
pansion. Endovascular repair involves less blood loss, less trauma to 
the patient and fewer days in intensive care unit than an open repair. As the 
endovascular stentgrafting does not involve a large abdominal incision, the patients 
do also recover faster. The recovery time is usually 1-2 weeks. Endovascular repair is 
also associated with fewer peri-operative (within the first 30 days) complications than 
traditional open treatment. However, patients who are treated with endovascular 
s  and maybe for the rest of 
4.2 
In recent years, endovascular surgery has also become an available treatment. As with
open repair, this method also excludes the aneurysm from the aortic bloodstream by 
attaching a graft. The procedure involves small incision in the patient’s groin and
insertion of small hollow tubes called catheters into the arteries (a). The self-
expanding stentgraft is moved through a sheet and passed up the pelvic arteries unt
it reaches the bulged area (b). The surgeon use live x-ray pictures viewed o
screen to guide the stent graft (Norwood et al. 2007). Similar to graft in an o
repair, the endovascular stent graft will also repair the blood vessels and protect 
against further ex
tentgraft must be kept under surveillance for many years
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their lives, due to stentgraft failures which may occur years after the primary 
treatment (Norwood, Lloyd, Bown, Fishwick, London, & Sayers 2007). 
 
Figure 6: Illustration of endovascular repair stent graft 
 
 
Not all patients can go through with an endovascular surgery. Special morphologi
requirements of the infrarenal neck and iliac arteries exclude approximately 30-50% 
of all patients with abdominal aortic aneurysm. Hence, pre-operative CT needs to b
carried out to measure lengths, diameters and angels in the different parts of the 
vessel (Krohg-Sørensen et al. 2002). Through open repair one can adjust and modi
to accommodate varying anatomic features. On the other hand, some patients will 
also be inoperable fo
c25 
e 
fy 
r open repair, and if eligible they will be treated with 
ndovascular surgery. These are typically elderly patients with limited life 
expectancy and high-risk patients with multiple co-morbidities (Green 2002;Zarins & 
Gewertz 2005). 
                                             
e
 
25 Morpholgy: The study of the anatomy and form of cells, organs and organism.  
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4.3 Treatment considerations 
The recommended threshold for referring patients to repair is AAA≥55 mm. 
However, some patients with this size of aneurysm may be considered inoperable du
to contraindications. The most common contraindications for elective repair of 
abdominal aortic aneurysm is myocardial infarction within the past six months, 
intractable congestive heart failure, intractable angina pectoris, severe pulmonary 
insufficiency with dyspnea at rest, severe chronic renal insufficiency and 
e 
incapacitating residual effects from stroke. The risk needs to be considered for each 
t 
se for more than 50 years with low failure rate. Graft failure of open 
repair is estimated to be as low as approximately 0.3% per year (Zankl, Schumacher, 
ined 
y 
patient, but is to a large extent disregarded in case of an emergency event (Ernst 
1993). 
The choice of treatment depends on many factors, such as durability, costs and 
mortality. Endovascular has an advantage towards open repair with respect to few 
peri-operative complications and shorter recovery time which will also be reflected in 
the costs related to shorter hospital stay. In contrast, endovascular repair will generate 
costs in terms of high price on implant, high preoperative costs, costs of lifelong 
surveillance and the need for re-interventions. The advantage of open repair is that i
has been in u
Krumsdorf, Katus, Jahn, & Tiefenbacher 2007). Available equipment and tra
staff are also important considerations which need to be made prior to open surger
(Visser et al. 2007). 
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5. ECONOMIC EVALUATION 
Elective repair is reported to be more successful than emergency repair. Hence, the 
preferred treatment strategy is to detect the aneurysm before it ruptures. Ultrasound 
y of AAA, but it needs to be evaluated. 
 care system is to provide health services of 
high quality to people who are in need of health care. This aim is reflected in the 
mption that 
 
 
led to necessary treatment if the expected costs are in a 
reasonable relationship with the effect of the intervention ( 1999;LOV 1999-07-02 nr 
e 
oth 
screening of a population at risk has been shown to reduce the incidence of ruptured 
AAA, but yet there is no screening programme in Norway (Ashton, Buxton, Day, 
Kim, Marteau, Scott, Thompson, & Walker 2002). Ultrasound screening may be one 
possible strategy to reduce the overall mortalit
The objective of the Norwegian health
health care expenditures which represents 9% of the gross domestic product in 
Norway (Statistics Norway 2008a). Nevertheless, there is still a gap between what is 
medically and technically feasible, and what is feasible with the resources available 
in the health care sector. Economics is based on the very fundamental assu
resources are scarce. Hence, a decision maker who commits resources to one use will 
implicitly deny the use of these resources for another. There is therefore a need for 
economic evaluation in order to decide how to allocate resources within the health
care sector. 
Several policy documents have addressed the issue of priority setting in the 
Norwegian health care system. According to the NOU 1997:18 (“Priority setting
revised”), priority settings among patients should be based on three criteria; the 
patient’s health condition, the expected outcome from treatment and the cost-
effectiveness. The latter implies that the ratio between cost and outcome should be 
reasonable. The Patient Right Act of 1999 also emphasizes this view. The act 
expresses that a patient is entit
63 1999). 
Economic evaluation is an aid for decision makers to address this issue. It can b
defined as “the comparative analysis of alternative courses of action in terms of b
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their costs and consequences” (Drummond 2005). The task is to choose among 
different alternative uses of scarce resources and involves identifying, measuring, 
valuing and comparing costs and consequences of the alternatives. 
In principle, there are there are three types of complete economic evaluation; cost-
benefit analysis, cost-utility analysis and cost-effectiveness analysis. The choice of 
approach is mainly dependent on the basis of information and how one measures the 
Cost-benefit analysis is grounded in welfare economic theory. The approach requires 
ive programmes are valued in monetary units. All 
comparable units, and the programmes are 
5.2 Cost-effectiveness analysis 
outcomes.  
5.1 Cost-benefit analysis 
that the consequences of the alternat
costs and consequences are expressed in 
analysed by directly comparing the incremental costs with its incremental 
consequences. CBA provides information on the absolute benefit of programmes and 
one can assess whether a programme is worthwhile, without reference to any external 
standards. The main objective of CBA is to identify projects where the net social 
benefit is positive, indicating that a programme is worthwhile (Drummond 2005).  
CBA is problematic when valuating health outcomes in monetary terms as it is 
difficult to assign the monetary value of health benefits. However, CBA has an 
advantage over CEA and CUA in that the method, in principle, has a broader scope 
when assigning values to the benefits. CEA and CUA are restricted to compare health 
programmes that assign values to health benefits such as QALYs, and their analysis 
mainly address production efficiency. In contrast, one may assign values to non-
health related goals in CBA.  
In cost-effectiveness analysis the outcome is measured in natural units, such as 
avoided fractures or life years gained. The costs are related to a single, common 
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effect that may differ in magnitude between the alternative programmes. CEA is 
considered as most convenient in situations where “a decision-maker, operating with 
a given budget, is considering a limited rang of options within a given field” 
mond 2005). The decision on whether a programme is worthwhile have to be 
 budget constraints or cost-
effectiveness threshold. 
er on the outcome side. CUA, in principle, measures 
benefits of a health care programme in terms of utility, in which the term utility refer 
 the preferences individuals and society may have for health outcomes (Drummond 
2005). CUA presents a more convenient technique than CBA in assigning the value 
of health benefits, as it allows for health-related quality of life adjustments of 
outcomes. Simultaneously, it provides a g neric outcome measure for comparison of 
costs and outcomes in different programmes. The health improvement is generally 
, 
grammes 
r 
rast 
e range health program that improve the 
(Drum
made in reference to an external standard, such as
CEA does not use generic measure of outcome, which makes it more difficult to 
make a comparison across studies. However, this issue can be solved by comparing 
health programmes with common effect, such as life years gained (Brearly S. & 
Johnson J.N 2008).  
5.3 Cost-utility analysis 
CUA can technically be seen as a specific type of CEA. The two methods are 
identical on the cost side, but diff
to
e
expressed as a common unit of measure such as quality-adjusted life-years (QALYs)
disability-adjusted life-years (DALYs) or similar measures. Such effectiveness 
measures enable CUA to incorporate both the changes in the quantity of life, 
(mortality) and the changes in the quality of life (morbidity). CUA is useful when 
measuring the total welfare, in the sense that it enables comparison of pro
for different conditions. 
CUA is in some fields considered as unethical as healthy people are given a highe
weight than people with severe conditions or chronic diseases. This is also in cont
with empiric findings, reporting that peopl
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life quality of people with severe diseases above health program that improve the 
quality of life of relatively healthy people (Grasdal A., Askildsen, & J.E. 2003). 
 
.3.1 Interpretations of study findings 
CBA is a useful technique for a decision maker to assess whether programmes are 
worthwhile by identifying projects where the net social benefit is positive. CEA and 
CUA, on the other hand, need external standards such as budget constraints or cost 
effectiveness ratio threshold. The decision maker uses the external standards to 
maximize the benefits with a given budget, by ranking the programmes according to 
their cost-effectiveness.  The method involves examination of the additional costs 
(the differences in costs with or without a particular programme) that one strategy 
imposes over the other, compared to additional effect (the difference between a health 
outcome with or without a particular programme). This is illustrated in Equation 1, 
where C = costs and E = effects. 
 
Equation  1: 
5
E
C
EE
CCICER Δ
Δ=−
−=
12
12  
When comparing the alternatives, one will consider the following four options (see 
Figure 8): I) Intervention is more effective and more costly than alternative O, II) 
Intervention is more effective and less costly than O, III) Intervention is less effective 
and less costly than O and IV) Intervention is less effective and more costly than O. 
Option II) dominates the alternatives and makes the choice more or less 
straightforward for the decision maker. The choice between alternative I and III will 
depend on the maximum cost-effectiveness ratio one is willing to accept, and is often 
referred to as the cost-effectiveness threshold (Drummond 2005). This value is a 
political or strategic value specifying the willingness-to-pay per life years gained 
(LYG). 
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Figure 7: Cost-effectiveness plane 
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6. RESEARCH QUESTION 
vious chapters, the research question of this thesis is: Adopting a 
 are the incremental costs and health consequences of 
-old men for abdominal aortic aneurysm in Norway 
Based on the pre
health care perspective, what
screening asymptomatic 65-year
compared to no-screening? 
The core issues in the economic evaluation are presented in the table below. 
 
Table 1: Core issues in economic evaluation 
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7. METHODS 
7.1 Model 
7.1.1 The Markov model 
In order to estimate the incremental costs and health consequences of a screening 
 aneurysm, I chose the Markov model as a decision 
rg & Beck 1993). Abdominal aortic aneurysm is a 
disease which involves a continuous and increasing risk of rupture. These factors 
The model had two strategies; screening or no screening. Furthermore, the model 
d:  
programme for abdominal aortic
analytic model. A Markov model is most useful when a decision problem involves 
risk that is ongoing over time, the timing of events is crucial, and when events may be 
repetitive (Hunink 2001;Sonnenbe
make the Markov model a more convenient way to structure the decision problem 
than alternatives, such as a decision tree. 
7.1.2 Structure of the model 
At the start of the simulation the cohort was distributed among the possible health 
states, and for each state the proportion of the cohort was portioned among all states 
according to their prevalence. The cycle length in the model was one year. 
assumed that a patient at any given point in time is in one, and only one, of a finite 
number of health states, called Markov states. Eleven health states were include
• AAA≤30mm 
• AAA 30–39 mm 
• AAA 40–54 mm 
• AAA 55-59 mm 
•  AAA≥60mm with risk factors 
• AAA≥60mm with unknown risk factors 
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• Inoperable AAA 55-59 mm 
• Inoperable AAA≥60 mm  
he 
e 
l other 
 the 
ngly 
and once an aneurysm greater than 55 
mm is detected, the patient will be referred for either elective endovascular or elective 
 
 
(see chapter 4) which will make it too risky for them to undergo a 
surgery. Patients in this state will be monitored until the aneurysm attains a diameter 
g 
ill 
Patients who were not included in a screening programme were assumed to be similar 
 those in the screening group, regarding risk of the different events. Some of the 
atients in the non-invited group will also have their aneurysms detected incidentally 
through physical examination or routine medical test. These patients will be included 
• Post EVAR 
• Dead from aneurysm  
• Dead from other causes  
The health states are mutually exclusive and collectively exhaustive, meaning that t
patient cannot be in more than one health state at the same time, but is always in on
of them. 
Patients categorized in the AAA≤30 mm state were defined as healthy, while al
patients were at risk of aneurysm rupture, or had aneurysm repair. The patients in
states AAA≥30mm will either stay in the same in the same state, or grow in the 
aneurysm and move (transit) to another state. The transition probability is stro
dependent on the initial size of the aneurysm 
open repair. Detected aneurysms under this threshold are subject to a monitoring
programme. 
Some patients will however, for various reasons, be unsuitable for surgery and were
categorized as inoperable. These patients are denied surgery because they have 
certain risk factors 
at which the risk of rupture is thought to outweigh the operative risk. Although bein
monitored, some of these patients will experience a rupture of the aneurysm, and w
have to undergo an emergency surgery.  
to
p
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in the same monitoring programme, as those who were attending the screening 
program
Patients undergoing a repair will either survive or die. Patients who undergo an open 
repair will transit to AAA≤30mm and were defined as healthy. Patients experiencing 
a successful endovascular repair will also be defined as healthy, but due to the 
acquired post-operative monitoring programme described in chapter 4, they will 
transit to the Post  EVAR state. These patients differ from patients who have 
undergone a successful open repair, because they more frequently experience post 
operative complication and must be kept under surveillance. Some patients in the 
Post EVAR state will also transit to the Secondary EVAR state. These patients may 
have complications that require a second intervention. The re-intervention may for 
some patients involve only a small adjustment of the graft, while others are be 
referred for a new surgery and this time they will be referred to open repair.  By 
defining these patients in a separate state, one solves the Markov property problem by 
assuming that the process has no memory for earlier cycles. If the repair was 
successful they will transit to AAA≤30mm.  
The model consisted of two death states in which the whole cohort ends after a 
neurysm”, while “Dead other 
causes” refers to non-AAA causes of death. The death stat are so-called absorbing 
is state, he or she cannot leave this state, but 
s and 
ed “no AAA” refers to the AAA≤30 mm state, while the 
. 
me in the first place. 
sufficient number of cycles. Patients who die from AAA before surgery or do not 
survive a repair will end up in the state “Dead from a
state because once a patient reaches th
will remain there.  
The state-transition diagram below illustrates the possible health states, event
transitions. The oval nam
oval named “small AAA” refers to the health state AAA30-39mm and 40-54 mm
The “large AAA” includes AAA 55-59 mm and AAA≥60 mm. 
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Figur 8: Model structure 
 
The ovals represent the health states, while the rectangles represent the events. Th
arrows show the possibl
e 
e transitions for the patient.  
7.1.3 Validation of the model 
In order to validate the model, I used data from Statistics Norway to compare the 
 
st 
 half-
mation 
of expected survival in the model. Hence, in order to compare the remaining life 
remaining life expectancy in the population to the remaining life expectancy 
predicted by the model.  
An important assumption made in discrete-time Markov models is that all state
transitions occur simultaneously, at the end of each cycle. In reality, however, mo
kinds of transitions occur gradually throughout a time interval and on average
way through (TreAge Software 2007). This assumption may result in overesti
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expectancy in the population, based on data from Statistics Norway, to the remaini
life expectancy predicted
ng 
 by the model, I implemented the half-cycle correction in the 
TreeAge Software. This adjustment allows you to divide every alive state’s 
al reward 
e model 
 
ic aneurysm, screening and cost-effectiveness. These key words 
were se evalence, 
incidence, sensitivity, specificity, treatment, risk factors, risk of rupture, expansion 
rate, natural history, costs, and ethics. Additionally, relevant references mentioned in 
the identified studies were explored. No publications were scrutinized by more than 
one student. Each Pubmed hit was studied with respect to relevance of title, and the 
abstract read in full if the title was relevant. When the title was relevant, full text 
articles were obtained. 
7.3 Probabilities 
l 
 Norway. When not, data were collected from countries in which the 
patients with the disorder and its natural course are in a comparable position. 
incremental reward in half, and assign the half reward as its initial and fin
In addition, I compared the number of AAA-related deaths as predicted by th
with those reported to Statistics Norway. 
7.2 Litterature search 
A systematic review of the literature was conducted to get an overview of relevant
aspects of the disease and the decision problem. The searches were undertaken 
January through May 2008 using the PubMed database. In general I used the key 
words abdominal aort
parately combined with additional terms such as epidemiology, pr
The probabilities used in this analysis are mainly collected through my literature 
search. Since my literature search revealed few Norwegian articles on abdomina
aortic aneurysm, most of the probabilities used in this analysis are collected from 
articles published outside Norway. However, I have when possible, used data 
collected in
Furthermore, all probabilities are evaluated by a medical expert opinion and 
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supplemented when needed. All probability parameters included in the model are 
reported in Appendix I. 
7.3.1 Prevalence of detected abdominal aortic aneurysm 
The Tromsø Study was the only Norwegian population-based study that has 
investigated the prevalence of AAA, that my literature revealed (Singh, Bonaa, 
 Solberg 2001). However, the study does not report detailed 
ize of the aneurysm. Hence, I collected these numbers from the 
 al. 
, is 
g to size from screening studies 
Jacobsen, Bjork, &
information on the s
MASS-study , supplemented with findings from Lederle and co-workers , Scott and 
co-workers and Henrikson and co-workers (Ashton, Buxton, Day, Kim, Marteau, 
Scott, Thompson, & Walker 2002;Henrikson M. & Lundgren F. 2005;Lederle et
1997;Scott, Ashton, & Kay 1991). The prevalence, in terms of size of aneurysm
presented in Table 2. 
Table 2: Prevalence of AAA accordin
 
These values are derived through population-based studies where people have been 
 these as prevalence numbers one needs to 
ms 
detected incidentally through physical examination or routine medical test. The 
screened. Hence, in order to consider
assume that the screening devices produce sensitivity and specificity values close to 
100 %, meaning that everyone that has an aneurysm larger than 30 mm will be 
detected.  
The non-screened patients who are not subject to screening will have their aneurys
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literature indicates that the yearly probability of being detected opportunistically 
range from 0.051(Henrikson et.al:2005) and 0.125 (Kim et al. 2007). The range is 
aneurysm and the detection rate. Hence, in the analysis I assumed that detection rate 
 
relatively wide, and may be explained by the correlation between the size of the 
increases with the size of the aneurysm. This can also be supported in the literature on 
diagnosis of AAA referred to in chapter 3.  
7.3.2 Rupture 
Several studies report the yearly probability of rupture. As the probability increases 
with age, the studies also provide size dependent rupture rates. Within each size
range, the probabilities vary slightly. One explanation for this variation may be 
different age structures in the studies. The probability of rupture is also gender 
dependent and may therefore result in variation in the probabilities. Size dependent 
rupture rates are presented in Table 3. 
Table 3: Rupture rate according to size from screening studies 
 
 
7.3.3 Background mortality 
Age and gender specific mortality for all causes from 2002 were used as backg
mortality. Due to lack on data on non-AAA mortality for patients who are inoperable 
from AAA, I used data for mortality among patien
round 
ts with cardiovascular diseases. 
These rates are reported from Statistics Norway and can be found in Appendix 4. 
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7.3.4 Clinically effectiveness 
ated on 
ctiveness has relied upon voluntary registers such as the UK 
Registry for Endovascular Treatment of Aneurysms and the European Collaborators 
 
called DREAM. The EVAR 1 Trials investigated patient at the age of at least 60 
 
l 
 
es vary to some extent between the studies, but 
, & Ballard 2005) to 75% (Silverstein, Pitts, Chaikof, 
ined by the complexity of a rupture 
situation. Depending on the circumstances for the patient who experiences the 
lar repair and open 
 the value I used in my model.  
Until recently, the research on clinical effectiveness has mostly been concentr
specific aspects on the treatment strategies. Furthermore, when endovascular repair 
became an available method most research has been dedicated on this method. 
Information on the effe
on Stent Graft Techniques for Abdominal Aortic Aneurysm Repair Register.   
However, in recent years several controlled trials of endovascular repair against open
repair have been initiated. In UK there are two multi centre trials (EVAR1 and 
EVAR2), which started in 1999 and in The Netherlands there is also a smaller trial 
years old with a diameter of 55 mm or more. They found a 30-day mortality of 1.5%
and 5.8% for endovascular repair and open repair respectively. The DREAM tria
found similar numbers, reporting a 30-day mortality of 1.2 % for endovascular repair
and 4.6 % for open repair (Greenhalgh et al. 2004;Prinssen, Buskens, & 
Blankensteijn 2002). The mortality rat
most studies report that the mortality rate for open repair is slightly higher than for 
endovascular repair. 
The mortality risk related to emergency repair, are mainly estimates from 
observational studies. From my literature search I found mortality risks varying from 
30% (Ashton, Buxton, Day, Kim, Marteau, Scott, Thompson, & Walker 
2002;Silverstein, Pitts, Chaikof
& Ballard 2005). This wide range may be expla
rupture, one will experience different mortality risks. However, most clinical 
guidelines operate with a mortality risk of 50% for both endovascu
repair. This is also
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7.4 Costs  
The cost estimating process in economic evaluation consists of three p
identification of the types of resources used in the health programme, quantification
of the cost components, and valuation of the components (assigning a monetary value
for each component). 
In the identification phase the costs relevant to the chosen perspective is identified. I
my analysis I excluded all indirect costs related to productivity loss and time
hases: 
 
 
n 
 
atient and family members (Time consumption of the patient is 
included in the sensitivity analysis) (Drummond 2005). Hence, this analysis identifies 
 
 
 rate of time preference, the costs were discounted. The 
Norwegian Ministry of Finance suggest using discount rate between 2.5-5% for 
s 
 
 screening patients and the cost of monitoring them.  
Cost of screening
consumption of the p
the resources from a health care perspective because of limitations of available data. 
The identification and quantification of costs included in the model were based on
discussions with vascular surgeons at Aker University Hospital. With respect to 
valuation and unit costs, I have used data from the Norwegian Medical Association, 
The Norwegian Ambulance Association, Capio Diagnostic and The Norwegian 
Labour and Welfare Administration.  
 In order to reflect a positive
economic evaluation (The Norwegian Ministry of Finance 2005). I discounted at 4% 
in my analysis. All costs were measured in Norwegian Kroner (NOK) and the range
of upper and lower bounds were determined by the base case value +/- 20 % rate. The 
costs are presented in Table 5. 
7.4.1 Cost of screening programme 
The screening programme will generate costs from particularly two components. That
is the cost of
 
  The cost of screening includes the cost of inviting the target individuals, including the 
invitation, and the ultrasound examination administration costs and the cost of the 
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cost. No screening programmes for AAA exist in Norway today, and I assumed tha
the administrative costs will be equal those of an ongoing programme for color
cancer (NOK160 per patient, Eline Aas, University of Oslo, personal 
commu
t 
ectal 
nication). Furthermore, I used experiences from screening programmes for 
AAA in Sweden (Ashton, Buxton, Day, Kim, Marteau, Scott, Thompson, & Walker 
dgren F. 2005). The unit cost of the ultrasound 
Cost of monitoring
2002;Henrikson M. & Lun
examination was based on the NAV26 fee schedule (NOK347 + NOK200 in patient 
co-payment) which represent in principle 40% of the total costs to society.  
 
nts 
 the 
unit cost of an out-patient-clinic visit is NOK700.  
e visit, I used fee schedules from the Norwegian Medical Association. 
Under the assumption that an ordinary patient visits their GP four times per year, I 
ivided the fixed per-patient fee by four and added the price of fee-for-service of the 
home visit. 
                                             
The monitoring cost depends on the size of the detected aneurysm. Based on expert 
judgment, I assumed that patients with an AAA 30-54 mm will be examined once a 
year. Patients with AAA 55-59 mm will be examined twice a year, while patie
who have AAA≥60 mm will be examined four times a year. This is partly due to the 
risk of rupture, but also motivated by the other risk factors. The examination consists 
of an ultrasound examination and a visit at the out-patient-clinic. NAV report that
7.4.2 Cost of rupture 
In case of rupture, the patients will need a home visit from their general practitioner, 
in addition to ambulance transport to the hospital. Some will also reach emergency 
repair. The ambulance cost was derived from The Norwegian Ambulance Association 
and the latest available unit cost is reported to be NOK9500. In order to calculate the 
cost of GP hom
d
 
26 The Norwegian Labour and Welfare Administration.  
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Not all patients reach surgery, but if they reach the hospital they will be examined 
with ultrasonography and in some cases also computed tomography. Vascular 
surgeons at Aker Hospital assume the fraction of patients who will need CT to be 
90%.  
7.4.3 Cost of repair 
I included two methods of repair; open repair and endovascular repair. The costs are 
higher for endovascular repair than open repair in terms of higher per-operative and 
examination costs after discharge from hospital (see Appendix II). However, within 
each method the peri-operative costs will be equal whether it is an emergency or 
elective repair. The cost difference between emergency and elective repair, how
is identified through the pre-operative and post-operative costs.  In distinction to the 
pre-operative costs of an emergency repair, which preliminary consist of US 
examination, the costs of an elective repair will also consist of a CT examination and 
an out-patient-clinic visit. The unit cost of a CT examination and an out-patient-clinic 
visit is reported in the NAV database to be NOK687 and NOK700, respectively. 
The post-operative costs between emergency and elective repair differ, as the number 
of days in the intensive care and ward unit is less for elective repair than emergency 
repair. This is illustrated in table 4. Furthermore, patients who are referred for an 
elective repair do also have a higher probability of successful repair than those 
referred for emergency. These patients will not only generate post-operative costs in 
terms of hospital stay, but will also need examinations after discharge from hospital 
shown in Appendix II. The cost of secondary interventions is also reported in 
Appendix II. 
 
 
 
 
ever, 
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Table 4: Post-operative costs 
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27 Table 5: Cost components included in the mode
 
 
                                              
27 Description of source abbrivation: AUH = Aker University Hospital, CD = Capio Diagnostic, NAV = The Norwegian 
Labour and Welfare Administration, NMA = Norwegian Medical Association, NAA = Norwegian Ambulance Association, 
EA = Expert opinion from Eline Aas 
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7.5 Cost-effectiveness threshold 
The decision on whether or not do adopt a screening programme should in principle 
e Norwegian Ministry of 
based 
d 
 
priority st. 
Althoug o help us determine whether or 
not to offer an intervention, other factors than economic efficiency also needs to be 
considered. When setting priorities, decision makers need to evaluate other issues 
such as ethics and equity. Hence, when one include these aspects in the evaluation, 
there will sometimes be good reasons for offering an intervention that has greater 
costs than NOK500 000 per life year gained, and there will also be good reasons not 
to offer an intervention that is cost-effective. 
be determined by the cost-effectiveness threshold. Th
Finance declares that the cost-effectiveness threshold represents the maximum value 
that the society is willing to spend in order to gain one unit of health benefit (The 
Norwegian Ministry of Finance 2005). The threshold value in this analysis is 
on the suggestion from the Norwegian Directorate of Health. They suggests the 
threshold to be NOK500 000 per LYG. Previously, the Ministry of Finance has 
suggested a threshold of NOK425 000 while Kristiansen and Gyrd-Hansen propose
NOK350 000 (Kristiansen & Gyrd-Hansen 2007;The Norwegian Ministry of Finance
2005).  
The benefit of such threshold is that it may help decision makers to give lower 
 to interventions with small health benefits and high opportunity co
h the cost-effectiveness threshold is a tool t
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8. RESULTS 
8.1 Cost and health consequences  
The average life time AAA-related cost of a 65-year-old patient in the non-screening 
group was NOK3010 (NOK2032 discounted) and NOK6074 (NOK4686) discounted 
in the screening group, resulting in incremental costs of screened patients of 
NOK2677 per patient. The life expectancy of a non-screened patient is 16.3832 years 
(11.7051 years discounted), while it was 16.4351 (11.7345 discounted) for a screened 
patient. The incremental life year gained was 0.029 which implies NOK90200 per 
additional life year gained. The model indicates that the life time risk of dying from 
AAA is 0.003 when screening is undertaken, compared to 0.008 when it is not (63 % 
reduction in AAA-related deaths). The main findings are presented in the Table 6. 
Table 6: Cost and consequences for AAA. All cost (Norwegian Kroner 
(NOK) 2007) and life years discounted at 4%. 
 
The results are shown in Figure 10, by means of the cost-effectiveness plane of the 
e line indicates the ICER.   programme options. The slope of th
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Figure 9: Cost-effectiveness plane of the programme options 
 
 
 
 
8.2 Sensitivity analysis 
Due to uncertainty in the parameter values, one-way sensitivity analyses were 
erformed for all parameters, to examine whether the conclusion would be altered by 
any realistic change in the parameter values (see Appendix III). The sensitivity 
upture of unscreened AAA≥60 mm with 
rupture of unscreened AAA 50-59 mm, the 
, 
p
analyses showed that the probability of r
unknown risk factors, the probability of 
probability of dying from aneurysm when emergency open repair and the cost of 
screening and invitation were the variables that had the greatest impact on the results
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but none of this uncertainty is large enough to threaten the conclusion that scr
for AAA is cost-effective (see Figure 11). For example, if the probability of rupture
of unscreened AAA≥60 with unknown risk factors was 0.1 (lower bound) it would 
result in an ICER of NOK81064 and if the probability of rupture of AAA 40-54 m
was 0.191 (upper bound) it would result in an ICER of NOK116844. If the co
eening 
 
m 
st of 
screening and invitation was reduced to NOK806 (lower bound) it would result in an 
OK83435 and if the cost of screening and invitation was increased to 
OK1208 (upper bound) it would result in an ICER of NOK97109. 
 general, the sensitivity analysis showed that the conclusion is less threatened by 
uncertainty in parameters partly based on assumptions, and more sensitive by 
parameters that were collected from published results.  
 
Figure 10: Tornado diagram of the most sensitive parameters 
ICER of N
N
In
Tornado Diagram at
Screening v. No Screening
Incremental Cost/Eff
kr73K kr88K kr103K kr118K
Probability of rupture of unscreened  AAA > 60 mm with unknown risk: 0,10 to 0,191
Probability of rupture of unscreened  AAA 55-59 mm: 0,05 to 0,11
Probability of dying from aneurysm when emergency open repair: 0,30 to 0,70
Cost of screening examination and invitation: 806 to 1208
Probability of dying before emergency repair when aneueysm ruptures: 0,4 to 0,6
Probability of being referred to secondary EVAR when Post EVAR: 0,064 to 0,151
Cost of successfull elective open repair: 106216 to 159324
Cost of successfull elective endovascular repair: 182872 to 274308
Probabilitt of AAA 55-59 mm, when AAA 40-54 mm: 0,1272 to 0,198
Probability of AAA > 60 mm with unknown risk factors being incidentally detected: 0,051 to 0,125
Probability of AAAA 40-54 mm when AAA 30-39 mm: 0,05 to 0,115
Probability of dying from aneurysm when elective open repair: 0,027 to 0,058
Cost of successfull secondary EVAR: 115042 to 172562  
 
8.3 Validation of the model 
Statistics Norway reports that the remaining life expectancy for 65-year-old men was 
15.929 in 2005 (see Appendix V), while the remaining life expectancy predicted by 
the model is 15.885 resulting in a difference of 0.044 (Statistics Norway 2002a). 
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Statistics Norway reports that t
2005(Statistics Norway 2005b). The model predicts that 
he number of AAA-related deaths was 106 in 
the life time risk of dying 
 
ted deaths is 168. 
 
 
. 
from AAA is 0.008. In 2008 the number of number of 65-year-old men in Norway
was 21057 (Statistics Norway 2008b). Assuming constant population cohort and 
mortality, the model predicts that the number of AAA-rela
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9. DISCUSSION 
The results of this model indicate that screening for AAA may be a cost-effect
technology. This conclusion, however, should be seen against the methodological 
limitations of the study, and the findings of other studies. 
9.1 Metholodical limitations 
9.1.1 Source of probabi
ive 
lities 
ew articles published in Norway, I had to collect 
most of my data from articles published in other countries. The collected articles were 
y 
tice 
ance to 
the nearest hospital compared to people in 
e 
 and 
e that the conclusion is less sensitive to variation in 
llected from published results. 
valuate the cost components I also used data from Norwegian Medical Association, 
Since my literature review revealed f
published in Western countries and, hence, there is no reason to believe that Norwa
differs considerable with regards to demography, epidemiology and clinical prac
compared to these countries. However, demographic differences, such as dist
the nearest hospital, may cause some differences in the results. The population in 
Norway experience a longer distance to 
most other industrialised countries, in which the population density is higher. The 
probability of dying from rupture is therefore likely to be higher in Norway. This 
difference will tend to make the benefit of screening in Norway greater than th
model would predict.  
Natural course of AAA is difficult to study and information on some probabilities is 
scarce. Some of the included probabilities were therefore based on assumptions
variation, and uncertainty in these parameters may affect the main result. However, 
the sensitivity analyses implicat
these parameters than those co
9.1.2 Source of costs 
The identification and quantification of the costs included in the model were made 
through discussions with vascular surgeons at Aker University Hospital. In order to 
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The Norwegian Ambulance Association, Capio Diagnostic and The Norwegian 
Labour and Welfare Administration. The valuation of the cost of a day of institutional 
care can be specific troublesome, in that the use of an average cost per day is 
9.1.3 Background mortality 
Age and gender specific mortality for all causes and cardiovascular diseases were 
r 
ortality among patients with cardiovascular 
diseases. This assumption may results in a shortened remaining life expectancy as the 
ing 
attendance rate may cause bias in the model, because a lower attendance rate means 
that the average screening cost per patient will be higher. However, several studies 
calculated on the basis of the institution’s entire annual case-load (Drummond 2005). 
This may cause bias of the actual cost estimates for the specific condition. In order to 
identify all important costs, measure them accurately in appropriate physical units, 
and value them credibly, one should seek to cost collect data from empirical studies 
of representative patient group. Due to time limitations, this was not feasible for my 
model. 
collected from 2002 (Ashton, Buxton, Day, Kim, Marteau, Scott, Thompson, & 
Walker 2002;Scott, Wilson, Ashton, & Kay 1995;Statistics Norway 2002b). 
However, there is little reason to believe that the mortality rates of men 65-100 years 
have changed significantly since 2002. 
Information obtained from studies of patients unfit for repair is incomplete. In orde
to find data on non-AAA mortality for patients who are inoperable from AAA, I 
therefore used national data for m
total mortality risk for cardiovascular diseases is higher than for patients considered 
unfit for repair of AAA. However, this assumption may be reasonable as these 
patients also have a risk of dying from other causes than cardiovascular diseases, such 
as cancer and kidney diseases. 
9.1.4 Attendance rate 
The model assumed 100% attendance rate from the invited men. Exclud
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have shown that the attendance rate have little effect on the cost-effectiveness ratio 
(Boll et al. 2003;Wanhainen et al. 2005). 
e 
on, Buxton, 
 Kay 
he 
9.1.5 Cost of repair 
osts related to productivity loss and time 
s related 
 
e place 
Another limitation of the model is the exclusion of helicopter cost, in case of a 
rupture. My model considers a cohort of 65-year-old men in the district of Oslo. The 
 hospital than people in the rest of the country. 
An important issue when discussing the attendance rate of a screening programme is 
the selection bias of the people who choose to attend. Several studies indicate that th
people who attend screening are healthier than those who not attend(Asht
Day, Kim, Marteau, Scott, Thompson, & Walker 2002;Scott, Wilson, Ashton, &
1995). The life expectancy of screened patients is considered as a key variable for t
cost-effectiveness ratio, and hence the cost-effectiveness may be high, despite a low 
attendance rate. 
In addition to exclude all indirect c
consumption of the patient and family members, I also excluded indirect cost
to the treatment. Another important exclusion was training costs. The training of 
students and house physicians takes place in the day time. Hence, in case of an 
emergency repair the cost of repair will be higher if the repair takes place in the day
time compared to in the night. This exclusion was made due to lack of data, as the 
time limitation did not allow me to do a counting on how many repairs that tak
in the day time and in the night. 
people in Oslo live closer to the nearest
Hence, in case of a rupture the men will be transported with ambulance and not 
helicopter as one will need in places with wider distances.  
The exclusion of training cost and helicopter cost, reduce the cost of emergency 
repair which makes the cost-effectiveness of screening less optimistic. 
 56
9.1.6 Rupture rate 
My literature search did not reveal articles on age-specific rupture rates. I therefore 
had to collect probabilities from various articles. Each of them only investigates a 
limited age group of the defined cohort in my model (men between 65 to100 years
and not the total group. There is reason to believe that demographic and 
epidemiological differences between t
) 
he cohorts may cause uncertainties in the 
included probabilities on rupture. However, none of the revealed articles from my 
f 
 
 
 
ed 
ed 
literature search investigated the rupture rate of the men in the very upper bound o
the cohort. As the risk of rupture increases with age, there is therefore no reason to 
believe that my model overestimates the risk of rupture.  
9.1.7 Exclusion of women 
The model did not include women. One may argue that excluding women is 
discriminating as women are also at risk of AAA. However, epidemiological studies 
report that the incidence and prevalence among women is significantly lower than
among men (Lederle, Johnson, Wilson, Chute, Littooy, Bandyk, Krupski, Barone,
Acher, & Ballard 1997;Singh, Bonaa, Jacobsen, Bjork, & Solberg 2001). Previous 
cost-effectiveness studies have concluded that the incidence have an effect on 
whether screening is considered as cost-effective, but screening women have also
shown to be cost-effective (Cosford & Leng 2007;Wanhainen et al. 2006). 
9.2 Strengths of the study 
My literature search did not reveal any cost-effectiveness studies which were bas
on Norwegian cost data. Furthermore, none of them included both endovascular and 
open repair as treatment options. As I have included Norwegian cost and consider
both methods in my analysis, this study may add new information to the research 
field. 
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9.3 Findings of other cost-effectiveness studies 
In order to validate the structure of the model, it is important to make a comparison 
 
es from other countries. In my study I captured both 
open repair and endovascular repair as treatment options. The studies identified in 
ing group compared to 27 in the control group, 
resulting in a 67 % reduction of AAA mortality during the first 52 months after 
y 
2003)  invited men in the Huntingdon 
1 and 1998. 50-year-old men were invited 
 
with results from other studies. When comparing studies, it is important to keep in
mind that the choice of input may have a large impact on the results. Particularly 
comparison between countries may differ with regard to demography, epidemiology 
and clinical practice (O'Brien 1997). 
No cost-effectiveness analyses for Norway have been identified. Hence, I had to 
compare my results with studi
Medline did only include one method. The two treatment methods involve a 
significant difference in cost, and may create different ICERs. 
Previous randomized controlled trials and non-randomized controlled trials indicate 
that screening men for AAA is cost-effective. Over a 4-year period Lindholdt and co-
workers (Lindholt et al. 2006) screened men aged 64-73 in the Viborg County in 
Denmark. 12,639 men were randomly selected to be invited for screening or not. 
Through ultrasound examination the study team detected men with aneurysm defined 
as AAA larger than 30 mm. During four years from the randomization there were 9 
AAA-related deaths in the screen
randomization. The estimated cost per saved life year was DKK 20 656. The stud
indicates a substantial long term benefit of screening for AAA. 
Wilmink and co-workers (Wilmink et al. 
District in UK for screening between 199
for screening for abdominal aortic aneurysm. During the study period, 71 deaths 
occurred as a result of ruptured AAA. 17 of the deaths were in the screening group, 
while 54 were in the control group. The screening programme resulted in 51 life-
years gained per year and a cost per life-year of $ 1173. Wilmink and co-workers
conclude that screening for AAA can be cost-effective in populations in which 
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incidence of ruptured aneurysm, in the absence of screening, is more than 5 per 
10000 person-years, and if screening can reduce the incidence by at least 50%. 
Other randomized clinical trials report that the program reduces the AAA-related 
 
e 
 
Boll and co-workers (Boll, Severens, Verbeek, & van, V 2003;Norman, Jamrozik, 
Lawrence-Brown, Le, Spencer, Tuohy, Parsons, & Dickinson 2004) designed a 
g for a cohort of men 60-65 
 
 in a 
e 
 parameter values.  
maining life expectancy reported in 
e between the prediction of the model and 
Statistics Norway is 0.044. This difference can partly be explained by the assumption 
mortality, but the reduction was not statistically significant. Scott and co-workers  
(Scott, Wilson, Ashton, & Kay 1995) report that a screening programme reduces the
mortality by approximately 50 %, while Norman and co-workers report that the ag
standardized mortality for those who actually attended the screening was 60 % lower
in the control group (Norman, Jamrozik, Lawrence-Brown, Le, Spencer, Tuohy, 
Parsons, & Dickinson 2004). 
Markov model to compare the effects of a single screenin
years in the Netherlands with the current no screening strategy. The life expectancy 
for men 60-65 years without screening was estimated to be 16.99 years beyond their
current age. The model calculated that the life expectancy for the men who were 
screened was 17.27 years, resulting in an average prolongation of life of 0.28 year. 
This life extension due to mass screening of AAA caused a cost of €334 resulting
cost of €1193 per life year gained. Boll and co-workers conclude that screening for 
AAA appears to be worthwhile. 
While all studies conclude that screening for AAA is cost-effective for men, th
ICERs vary somewhat because of differences in study design and
9.4 Validation of the model 
The remaining life expectancy predicted in the model is somewhat lower that the 
reported remaining life expectancy reported from Statistics Norway. When evaluating 
the validation of the model, I want the predicted remaining life expectancy from the 
model to be close to equal to the reported re
Statistics Norway. I found that the differenc
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made on the non-AAA mortality of inoperable patients. With available data we would 
l still 
dicted mortality from the model may be explained by 
of AAA and AAA mortality. This may tend to make 
 
 criteria presented in chapter 5, I 
onclude that screening 65-year-old men for this disorder fulfil the cost-effectiveness 
 However, cost-
r 
 a 
probably have experienced a smaller difference, but one can argue that the mode
predicts valid information on the population. 
Regarding the AAA related deaths, the model predicts 168, while Statistics Norway 
report 106. In chapter 2 I discussed the estimates of AAA mortality and argued that 
the reported mortality may be hampered by low rates of post mortems. From this 
argument, one would expect that the model would predict a higher number of AAA 
related deaths than 168. The pre
too low included probabilities 
the benefit of screening in Norway greater than the model would predict.  
9.5 Policy implications and conclusion 
My results indicate that screening 65-year old men for abdominal aortic aneurysm is 
cost-effective. The sensitivity analyses also indicate that the result is not threatened
by any realistic change in all variables. Based on the
c
criteria in the priority setting guidelines discussed in chapter 7.5.
effectiveness is not the only criterion that should be fulfilled. As presented in chapte
3, WHO has defined screening as a medical investigation that does not arise from
person’s request for advice for specific symptoms or complaints. Hence, they 
recommend that the following basic criteria should be fulfilled:  
1. The disease should be an important health problem: 
In chapter 2 I presented the epidemiology of AAA, showing that the disorder is the 
ause of 1.3% of all deaths among men in the age of 65-85 in developed countries. 
eaths, and it is also likely to 
 
c
Among elderly men it may cause as many as 2% of all d
assume that magnitude of the health problem is underestimated (Earnshaw et al. 
2004). Due to low prevalence of AAA, women are generally not considered as 
suitable target group for AAA screening.  
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2. A generally acceptable method of treatment must be available: 
In chapter 4 I presented the available treatment methods for AAA. I will not go 
rther into the methods, but both open repair and endovascular repair are effective 
old standard, as there is still 
, 
pairs 
 2006 were done with endovascular technique (Norkar & Norwegian Society for 
fu
and extensively used. Open repair is considered as the g
more to be learned about the endovascular technique with regards to complications
follow-up routines and re-interventions (Bergqvist, Bjorck, & Wanhainen 2008). 
However, according to the Norwegian Vascular Registry 32% of all elective re
in
Vascular Surgery 2006).  
 
3. The policy of treatment must be clear: 
An individual approach is recommended, but the threshold of AAA 50-55 mm for 
lective repair is reported to generally agreed on by in several studies (Brown 
undholm J., Hatlinghus S., 
e
P.T.MD, David T.Zelt MD, & Boris Sobolev PhD 2003;L
Wirsching J, Amundsen S., Staxrud L.E., Gjølberg T., Hafsahl G., Oskarsson W., 
Krohg-Sørensen, Brekke M., & Myhre H.O. 1999). 
 
4. Provision for diagnosis and treatment must be available: 
The screening strategy affects the demand for resources. Bergqvist and co-work
report tha
ers 
t screening elderly men has reduced the demand of resources to repair 
ptured AAA by 50%, but increased the number of elective repairs by 100-400% 
thermore, a greater proportion of 
 emergency repair. When 
ore patients undergo endovascular repair, the demand for surveillance program after 
ru
(Bergqvist, Bjorck, & Wanhainen 2008). Fur
elective repair is done with endovascular technique than
m
EVAR will increase. 
 
5. The disease must have a detectable latent stage: 
AAA involves several years of expansion before the aneurysm reaches the stage, 
where there is a risk of rupture. Bergqvist and co-workers report that 70% of all 
creening detected AAA is less than 40 mm, and that 2/3 of all screening detected s
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AAA never reaches the size of elective repair or rupture (Bergqvist, Bjorck, & 
Wanhainen 2008). 
 
6. A suitable screening method must be available: 
The screening method should show high accuracy, be rapid, inexpensive and safe 
(Bergqvist, Bjorck, & Wanhainen 2008). In chapter 3 I discussed these criteria with 
regards to ultrasonography and concluded that the method fulfills the criteria. 
 
7. The screening method must be accepted by the target population: 
8. The natural course of the disease must be known:
Ultrasonography has proven to be well accepted in several population-based 
screening studies, with attendance rates above 75% in most cases (Bergqvist, Bjorck, 
& Wanhainen 2008).  
 
 
atient carrying the disease. In chapter 1 I presented the most important factors 
redicting rupture and discussed risk factors for atherosclerosis and AAA. I will not 
o further into these factors in this section, but summarize that less than 20% of all 
AAAs eventually ruptures, and that AAAs less than 55 mm have a low risk of 
ure. 
9. The program must be cost-effective:
The natural course of AAA includes both aspects on the aneurysm, as well as the 
p
p
g
rupt
 
 
pters 8 and 9.3 
10. The treatment of the disease should favour the prognosis of the patients:
This criteria is already discussed in cha
 
 
 chapter 1 and 3 I showed that the overall mortality of rupture is high. Elective 
surgery, in appropriately selected individuals will therefore prevent rupture and 
improve life expectancy. Furthermore, the long term survival after successful elective 
repair is only slightly shorter than that of an age-matched general population. 
 
In
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Although screening for A
effective criteria, some fact
AA seems to fulfill the WHO criteria and fulfill cost-
ors may make screening ineffective. Such factors may be 
le. Elderly people may be skeptical and do not 
see the value of attending such program. An invitation to screening may also have 
adverse r 3. Even though screening 
for AAA may cause a reduction in aneurysm related mortality, a screening program 
will also result in some people having surgery for aneurysms that would not have 
ruptured during their lifetime (Brearly S. & Johnson J.N 2008). 
 
Based on these criteria, AAA seems suitable for a screening program. This is, 
however, only true for elderly men. The optimal age has not yet been established, but 
men around 65 years seems to a suitable target group (Bergqvist, Bjorck, & 
Wanhainen 2008).  
 
The conclusion of this study is that screening 65-year-old men is cost-effective.  
 
 
 
  
 
 
 
 
poor attendance rate by elderly peop
 effect on the quality of life, as discussed in chapte
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10. APPENDIX 
Appe
Table 7: Table of probabilities included in the model 
ndix I: Probabilities 
 
 
 64
Appe
Table 8: Pre-operative costs, secondary intervention 
   
ndix II: Costs28 
 
Table 9: Peri-operative costs 
 
 
 
                                              
28 Description of source abbreviation: AUH = Aker University ospital, CD = Capio Diagnostic  H
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Table 10: Examination costs after discharge from hospital 
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Appe
Table 11: One-way sensitivity analysis on all cost parameters 
ndix III: Sensitivity analysis 
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Table 12: One-way sensitivity analysis on all probability parameters 
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Appe
Table 13: Background mortality, all causes 
ndix IV: Background mortality 
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Table 14: Background mortality, cardiovascular diseases 
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Appendix V: Validation of the model29 
Table 15: Remaining life expectancy 
 
Remaining life expectancy = 15,929359 
                                              
al probability 
 
29 Description of validation components: Survival probability population = 1-mortality risk, Conditional surviv
= Survival probability population, current year x Survival probability population, next year 
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